Chelsea Therapeutics to Present at the 2013 Wedbush Life Sciences Management Access Conference

Chelsea Therapeutics to Present at the 2013 Wedbush Life Sciences Management
Access Conference

CHARLOTTE, N.C., Aug. 7, 2013 (GLOBE NEWSWIRE) -- Chelsea Therapeutics
International, Ltd. (Nasdaq:CHTP) is scheduled to present at the 2013 Wedbush
Life Sciences Management Access Conference at 10:20 AM on Wednesday, August
14, 2013 at Le Parker Meridien hotel in New York.

Joseph G. Oliveto, Interim Chief Executive Officer will provide a corporate
update and an overview of the Northera™ (droxidopa) development program.

Mr. Oliveto's presentation will be webcast live and archived for 30 days on
Chelsea's website, www.chelseatherapeutics.com.

About Chelsea Therapeutics

Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company
that acquires and develops innovative products for the treatment of a variety
of human diseases, including central nervous system disorders. Chelsea is
currently pursuing FDA approval in the U.S. for Northera™ (droxidopa), a
novel, late-stage, orally-active therapeutic agent for the treatment of
symptomatic neurogenic orthostatic hypotension in patients with primary
autonomic failure. For more information about the Company, visit
www.chelseatherapeutics.com.

CONTACT: Investors:
         Fara Berkowitz/Susan Kim
         Argot Partners
         212-600-1902
         fara@argotpartners.com
         susan@argotpartners.com
        
         Media:
         David Pitts
         Argot Partners
         212-600-1902
         david@argotpartners.com

Chelsea Therapeutics Logo
 
Press spacebar to pause and continue. Press esc to stop.